XMT-1522 Late-breaker at AACR in April... <br> <br> LB-294 / 16 - Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2 <br> <a href="http://www.abstractsonline.com/pp8/#!/4562/presentation/10611" rel="nofollow noopener noreferrer ugc" target="_blank">http://www.abstractsonline.com/pp8/#!/4562/presentation/10611</a> <br> <br> <br> Also poster on differentiation of ADC platform... <br> 754 / 21 - Unique pharmacologic properties of Dolaflexin-based ADCs—a controlled bystander effect <br> <a href="http://www.abstractsonline.com/pp8/#!/4562/presentation/3082" rel="nofollow noopener noreferrer ugc" target="_blank">http://www.abstractsonline.com/pp8/#!/4562/presentation/3082</a> <br>